The Global HIV/AIDS Market Outlook to 2012

Table of Contents

• Patient potential
• Global market analysis
• Pipeline analysis
• Competitive landscape

• Summary
• Introduction
• HIV/AIDS
• Overview
• Diagnosis, treatment and management
• Epidemiology
  • The global picture of HIV/AIDS
  • The seven major markets
• Forecast epidemiology
  • The seven major markets
  • Emerging markets

• Summary
• Introduction
• Market analysis by country
• Licensing trends
• Market analysis by drug class
• Key events in the global HIV market
• Combivir loses blockbuster status
• FDA approves the first once-daily triple-combination pill for the treatment of
• HIV
• Fuzeon, the first-in-class fusion inhibitor enters the HIV market, offering an additional treatment option for patients requiring salvage therapy
• Approval of maraviroc
• Leading brand dynamics
• Leading brands of HIV treatments
• Market dynamics of leading nucleoside reverse transcriptase inhibitors Key NRTI brands
• Market dynamics of leading protease inhibitors Key protease inhibitor brands analysis
• Market dynamics of non nucleoside reverse transcriptase inhibitors Key NNRTI brands analysis
• HIV therapeutic market sales forecasts to 2011

• Summary
• Introduction
• Key trends in R&D
• The HIV therapeutic area pipeline
• Leading drugs in development
• Classification of pipeline products
  • Entry inhibitors
  • Maturation inhibitors
  • Integration inhibitors
  • New agents from existing classes
• Profiles of key pipeline products
• Phase II compounds
  • Bevirimat (PA-457)
• Phase III compounds
  • etravirine (TMC-125)
• Isentress (raltegravir)
• Recently marketed drugs/drugs in registration
• Maraviroc
• Prezista (darunavir)
• Atripla (efavirenz/ tenofovir/emtricitabine)
• Fuzeon (enfuviritide)
• Pipeline forecasts
• Factors affecting forecasts
• HIV pipeline forecasts

• Summary
• Introduction
• Company market shares
• GlaxoSmithKline
• Overview
• Sales focus by drug class
• Marketed product portfolio
• R&D pipeline analysis
• Strategic and growth analysis
  • Drivers of growth
  • Resistors of growth
• Gilead
• Overview
• Sales focus by drug class
• Marketed product portfolio
• R&D pipeline analysis
• Strategic and growth analysis
• Drivers of growth
• Resistors of growth
• Bristol-Myers Squibb
• Overview
• Sales focus by drug class
• Marketed product portfolio
• R&D pipeline analysis
• Strategic and growth analysis
  • Drivers of growth
  • Resistors of growth
• Abbott
• Overview
• Sales focus by drug class
• Marketed product portfolio
• R&D pipeline analysis
• Strategic and growth analysis
  • Drivers of growth
  • Resistors of growth
• Roche
• Overview
• Sales focus by drug class
• Marketed product portfolio
• R&D pipeline analysis
• Strategic and growth analysis
  • Drivers of growth
  • Resistors of growth
• Boehringer Ingelheim
• Overview
• Sales focus by drug class
• Marketed product portfolio
• R&D pipeline analysis
• Strategic and growth analysis
  • Drivers of growth
  • Resistors of growth
• Pfizer
• Overview
• Sales focus by drug class
• Marketed product portfolio
• R&D pipeline analysis
• Strategic and growth analysis
  • Drivers of growth
  • Resistors of growth
• Merck
• Overview
• Sales focus by drug class
• Marketed product portfolio
• R&D pipeline analysis
• Strategic and growth analysis
  • Drivers of growth
  • Resistors of growth
• Barr
• Overview
• Marketed product portfolio
• R&D pipeline analysis
• Strategic and growth analysis
  • Drivers of growth
  • Resistors of growth
• Kohl Medical AG
• Overview
• Sales focus by drug class
• Marketed product portfolio
• R&D pipeline analysis
• Strategic and growth analysis
  • Drivers of growth
  • Resistors of growth

• Regional country groupings (UNAIDS)
• IMS data
• J5C HIV
• Index

• Figure 1.1: The HIV lifecycle
• Figure 1.2: Comparison of HIV treatment regimens
• Figure 1.3: Drivers of switching from first- to second-line ARV treatment regimens
• Figure 1.4: Estimated number of people living with HIV globally, 2005
• Figure 1.5: Unmet need for ARV therapy among adults in developing and transitional countries, 2005
• Figure 1.6 HIV patient segmentation across the seven major markets, 2005
• Figure 2.7: Global HIV/AIDS market share by geography, 2006
• Figure 2.8: Sales of types of HIV/AIDS brands, 2005-06
• Figure 2.9: Competitive dynamics of the global HIV/AIDS market by drug class, 2006
• Figure 2.10: Competitive dynamics of the leading treatments in the global HIV market, 2005-6
• Figure 2.11: Competitive dynamics of the leading NRTI brands in the global HIV market, 2005-6List of Tables
• Figure 2.12: Competitive dynamics of the leading protease inhibitor brands in the global HIV market, 2005-06
• Figure 2.13: Competitive dynamics of the leading NRTI brands in the global HIV market, 2005-6
• Figure 3.14: Prevailing R&D approaches, 2006
• Figure 3.15: The HIV pipeline by indication and stage of development, 2006
• Figure 3.16: Leading recently launched products and late-stage R&D compounds indicated for the treatment of HIV, 2006
• Figure 4.17: Competitive dynamics of the leading players in the global HIV market, 2006
• Figure 4.18: GSK' s HIV sales, 2006
• Figure 4.19: Gilead' s HIV sales, 2006
• Figure 4.20: BMS' HIV sales, 2006
• Figure 4.21: Abbott' s HIV sales, 2006
• Figure 4.22: Roche' s HIV sales, 2006
• Figure 4.23: Boehringer Ingelheim' s HIV sales, 2006
• Figure 4.24: Pfizer' s HIV sales, 2006
• Figure 4.25: Merck' s HIV sales, 2006
• Figure 4.26: Kohl' s HIV sales, 2006

• Table 1.1: Estimated prevalence of HIV/AIDS across the seven major markets, 2005
• Table 1.2: Forecast epidemiology of HIV/AIDS across the seven major markets, 2005-11
• Table 2.3: Breakdown of the global HIV market by drug class, 2002-06
• Table 2.4: Leading treatments in the global HIV market,
• Table 2.5: Leading NRTI products in the global HIV market, 2005 06
• Table 2.6: Leading protease inhibitor products in the global HIV market, 2005 06
• Table 2.7: Leading NNRTI products in the global HIV market, 2005 06
• Table 2.8: HIV treatment sales forecast, 2006-12
• Table 3.9: HIV pipeline forecasts, 2006-12
• Table 4.10: Leading players in the global HIV market, 2005-06
• Table 4.11: GSK' s HIV product portfolio, 2005-06
• Table 4.12: GSK' s HIV R&D product pipeline, 2006
• Table 4.13: Gilead' s HIV product portfolio, 2005-06
• Table 4.14: Gilead' s HIV R&D product pipeline, 2006
• Table 4.15: BMS' HIV product portfolio, 2005-06
• Table 4.16: BMS' HIV R&D product pipeline, 2006
• Table 4.17: Abbott' s HIV product portfolio, 2005-06
• Table 4.18: Roche' s HIV product portfolio, 2005-06
• Table 4.19: Roche' s HIV R&D product pipeline, 2006
• Table 4.20: Boehringer Ingelheim' s HIV product portfolio, 2005-06
• Table 4.21: Boehringer Ingelheim' s HIV R&D product pipeline, 2006
• Table 4.22: Pfizer' s HIV product portfolio, 2005-06
• Table 4.23: Pfizer' s HIV R&D product pipeline, 2006
• Table 4.24: Merck' s HIV product portfolio, 2005-06
• Table 4.25: Merck' s HIV R&D product pipeline, 2006
• Table 4.26: Barr' s HIV product portfolio, 2005-06
• Table 4.27: Kohl' s HIV product portfolio, 2005-06